Research
Hormonal
Pycnogenol (100 mg/day) reduces blood glucose levels and improves endothelial function in Type 2 Diabetes patients when used as an adjunct to conventional oral antidiabetic drugs, without increasing insulin secretion.
If you have Type 2 Diabetes, adding 100 mg of Pycnogenol daily to your existing medication regimen may help lower blood sugar and improve blood vessel health over a 3-month period. It works by slowing sugar absorption rather than forcing your body to produce more insulin.
GoodSupportsHIGH confidence
Pycnogenol (100 mg/day for 3 months) in addition to conventional treatment with oral antidiabetic drugs reduced blood glucose levels and improved endothelial function in patients with T2DM. Moreover, this reduction in glycemia was dose dependent without increasing insulin secretion [29, 30].
Why this rating
The paper cites specific clinical trials ([29, 30]) demonstrating dose-dependent effects in T2DM patients.
Source
Natural Products for the Treatment of Type 2 Diabetes Mellitus
José Luis Rı́os et al. · Planta Medica · 2015
DOI 10.1055/s-0035-1546131
narrative_reviewCited 445×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Phlorizin, derived from unripe apples, reduces postprandial glucose response approximately two-fold and increases urinary glucose excretion fivefold in healthy volunteers within 2-4 hours of ingestion.Good
- Galegine, isolated from Galega officinalis, has a chemical structure similar to metformin and is responsible for the blood glucose-lowering effects of the plant extract.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →